<DOC>
	<DOC>NCT01995032</DOC>
	<brief_summary>The purpose of the study is to show that the intake of L-citrulline and metformin improves muscle function and delay of progression in patients with Duchenne's muscular dystrophy.</brief_summary>
	<brief_title>L-citrulline and Metformin in Duchenne's Muscular Dystrophy</brief_title>
	<detailed_description>This is a single center, randomized, double-blind, placebo controlled study. The study medication consists of L-citrulline and metformin, respectively placebo given orally; 2.5 g L-citrulline or placebo will be given 3 times daily, metformin containing 250 mg or placebo will be administered 3 times daily. The duration of the study is 26 weeks and comprehends one screening and three study visits.</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Molecular diagnosis of DMD Patients 7 10 years of age at time of screening Ambulant Ability to walk 150 m in the 6 min walking distance (6MWT) D1 subdomain of the MFM scale &gt;40% stable treatment with steroids for &gt;6 months or steroid na√Øve patients Previous (3 months or less) or concomitant participation in another therapeutic trial Use of Lcitrulline, Larginine or metformin within the last 3 months Known individual hypersensitivity to Lcitrulline or metformin known or suspected malignancy Other chronic disease or clinical relevant limitation of renal, liver, heart function according to discretion of investigator start of cortisone treatment or change in dosage &lt;6 months prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Duchenne's muscular dystrophy</keyword>
	<keyword>DMD</keyword>
</DOC>